1. Tofacitinib is a JAK1/JAK3 inhibitor.
2. Study found inhibition of inflammatory cytokines in RA models.
3. Observed lack of effect on endothelial prothrombotic activation.
4. IL-17A showed resistance to tofacitinib’s effects.
5. Tissue Factor expression remained unchanged.
6. Concerns regarding cardiovascular risks persist.
7. Need for combination therapies targeting coagulation pathways highlighted.
8. Effective control of RA symptoms does not ensure cardiovascular safety.

Source: ACR Open Rheumatology